Stocks · News reference

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70

Oct 29, 2026, 1:22 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 28, 2026, 5:02 PM
Genmab Announces Positive Phase 3 Results for Petosemtamab Combination
Genmab reported that its Phase 3 LiGeR-HN1 trial of petosemtamab in combination with pembrolizumab met both primary endpoints in patients with first-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
GMAB
Fiscal.aiOct 28, 2026, 5:02 PM
AlphaValue/Baader Europe Downgrades Genmab to Reduce
AlphaValue/Baader Europe has downgraded its rating for Genmab A/S to "Reduce" on October 28, 2026.
GMAB
BenzingaOct 26, 2026, 5:02 PMBenzinga Newsdesk
TD Cowen Maintains Buy on Genmab, Raises Price Target to $52
GMAB